


Pioneering Research and Development in the Treatment of Addictions

R&D PUBLICATIONS



Our mission is to discover and develop innovative medications that help transform patients' lives through our industry-leading understanding of addiction and its co-morbidities.

We are constantly investigating new areas of understanding, new approaches to addiction treatment and new methodologies to support measurement of clinical response. Our latest thinking, journals and studies in these areas include:

Treatment of Substance Use Disorder

1

TITLE OF ARTICLE

Indivior: pioneering research and development in the treatment of addictions

> <http://bit.ly/1QuufKi>

AUTHOR

Christian Heidbreder, Rolley E. Johnson, Chris Chapleo and Paul J. Fudala

PUBLISHERS

Nature, 522 (7557): Supp. S45-S63

Treatment of Opioid Use Disorder

2

TITLE OF ARTICLE

A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of rbp-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence

> <http://bit.ly/1l7vUJN>

AUTHOR

Nasser AF, Heidbreder C, Gomeni R, Fudala PJ, Zheng B, Greenwald MK (2014)

PUBLISHERS

J. Clin. Pharmacokinetics, 53(9): 813-824

3

TITLE OF ARTICLE

Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (child-pugh classes a, b, and c), in hepatitis c virus-seropositive subjects, and in healthy volunteers

> <http://bit.ly/1NdyhkR>

AUTHOR

Nasser A, Heidbreder C, Liu Y, Fudala PJ (2015)

PUBLISHERS

J. Clin. Pharmacokinetics, 54(8): 837-849

4

TITLE OF ARTICLE

Population pharmacokinetic modelling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder

> <http://bit.ly/1WRtKJS>

AUTHOR

Laffont CM, Gomeni R, Heidbreder C, Jones JP 3rd, Nasser AF (2015)

PUBLISHERS

J. Clin. Pharmacol., Oct 19th, Electronic publication ahead of print



Treatment of Psychiatric Co-Morbidities

5

TITLE OF ARTICLE

Population pharmacokinetics and prediction of dopamine d2 receptor occupancy after multiple doses of rbp-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment

> <http://bit.ly/1iCNJ1v>

AUTHOR

Laffont CM, Gomeni R, Heidbreder C, Fudala PJ, Nasser AF (2014)

PUBLISHERS

Clin. Pharmacokinetics, 53(6): 533-543

Rescue Medications

6

TITLE OF ARTICLE

Liquid chromatography/tandem mass spectrometry method for simultaneous determination of cocaine and its metabolite(-)ecgonine methyl ester in human acidified stabilized plasma samples

> <http://bit.ly/1Rv24sU>

AUTHOR

Liu Y, Zheng B, Strafford S, Orugunty R, Sullivan M, Gus J, Heidbreder C, Fudala PJ, Nasser A (2014)

PUBLISHERS

J. Chromatogr. B. 961: 77-85

7

TITLE OF ARTICLE

A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: Pharmacokinetic profile of RBP-8000 and cocaine and effects of RBP-8000 on cocaine-induced Physiological effects

> <http://bit.ly/1NPIGpN>

AUTHOR

Nasser A, Fudala PJ, Zheng B, Liu Y, Chen Y, Heidbreder C (2014)

PUBLISHERS

J Addict Dis., 33(4): 289-302

Early Stage Discovery & Development

8

TITLE OF ARTICLE

Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of drug addiction

> <http://bit.ly/1MHf9RW>

AUTHOR

Heidbreder C (2013)

PUBLISHERS

Naunyn-Schmiedeberg's Archives of Pharmacology, 386: 167-176



Indivior PLC
Global Headquarters: The Fairfax Building,
10710 Midlothian Turnpike, Suite 430, Richmond, VA 23235, USA
Registered Office: 103-105 Bath Road, Slough, Berkshire, SL1 3UH UK
www.indivior.com